Drug Landscape ›
Dasatinib 100 MG ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 15
Most-reported reactions
Diarrhoea — 2 reports (13.33%) Hypertension — 2 reports (13.33%) Nausea — 2 reports (13.33%) Pyrexia — 2 reports (13.33%) Vomiting — 2 reports (13.33%) Abdominal Pain — 1 report (6.67%) Abscess Neck — 1 report (6.67%) Anaemia — 1 report (6.67%) Aphthous Stomatitis — 1 report (6.67%) Aspiration Pleural Cavity — 1 report (6.67%)
Source database →
Dasatinib 100 MG in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Dasatinib 100 MG approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Dasatinib 100 MG in United States?
Cedars-Sinai Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.